On February 19, 2021, Hillhouse Capital Management, Ltd announced that Cellular Biomedicine Group, Inc. filed a Certificate of Merger with the Secretary of State of the State of Delaware, pursuant to which the Merger became effective. Further, Hillhouse Capital added that as of the effective time of the Merger, each share of the Company’s Common Stock issued and outstanding prior to the effective time, other than the excluded shares (as defined in the Merger Agreement) that have been cancelled for no consideration, has been converted into the right to receive $19.75 per share in cash, without interest and net of any applicable withholding taxes.